- Report
- February 2025
- 200 Pages
Global
From €4195EUR$4,490USD£3,549GBP
- Report
- February 2025
- 182 Pages
Global
From €4204EUR$4,500USD£3,556GBP
- Report
- January 2025
- 210 Pages
Global
From €4666EUR$4,995USD£3,948GBP
- Report
- January 2025
- 120 Pages
United States
From €2326EUR$2,490USD£1,968GBP
- Report
- February 2021
- 117 Pages
United States
From €4624EUR$4,950USD£3,912GBP
- Report
- October 2024
- 98 Pages
Global
From €3500EUR$4,013USD£3,065GBP
- Report
- April 2025
- 50 Pages
Global
From €2476EUR$2,650USD£2,094GBP
- Report
- September 2024
- 320 Pages
Global
From €2480EUR$2,655USD£2,098GBP
- Report
- May 2022
- 284 Pages
Global
From €3229EUR$3,456USD£2,731GBP
Etomidate is an intravenous anesthetic drug used for induction of general anesthesia. It is a short-acting, non-barbiturate hypnotic agent that produces rapid onset of anesthesia with minimal cardiovascular and respiratory depression. It is commonly used for short surgical procedures, such as endoscopy, and is also used for rapid sequence intubation. Etomidate is metabolized by the liver and excreted by the kidneys, and has a relatively short duration of action.
Etomidate is one of several anesthetic drugs used in the market, which also includes barbiturates, benzodiazepines, and propofol. It is often used in combination with other drugs to provide a balanced anesthetic effect. Etomidate is generally considered to be a safe and effective anesthetic drug, with few side effects.
Some companies in the Etomidate market include Hospira, Mylan, Fresenius Kabi, and Teva Pharmaceuticals. Show Less Read more